Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05862285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Study acronym: UmbrellaMAX
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoints: details revised at 1 of 2 entries Trial sites expanded: 73 → 77 locations · Eligibility criteria expanded, about 11 words Show 2 more changesShow less
    • Trial sites expanded: 73 → 77 locations
    • Eligibility criteria expanded, about 11 words
  2. Trial sites expanded: 68 → 73 locationsv44
  3. Study sites: 67 to 68v43
  4. Trial sites expanded: 62 → 67 locationsv42
  5. Trial sites expanded: 58 → 62 locationsv41
Show 39 earlier versionsHide 39 earlier versions
  1. Study sites: 57 to 58v40
  2. Study sites revised (57)v39 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 1 of 57 sitesv38
  4. Study sites: 55 to 57v37
  5. Study sites: 51 to 55v36
  6. Enrollment target: 60 to 100 Study sites: 48 to 51 · Interventions: Atezolizumab (Drug), Bevacizumab (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug), Tiragolumab and… to Atezolizumab (Drug), Bevacizumab (Drug), Divarasib (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug)…v35 Show 2 more changesShow less
    • Study sites: 48 to 51
    • Interventions: Atezolizumab (Drug), Bevacizumab (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug), Tiragolumab and… to Atezolizumab (Drug), Bevacizumab (Drug), Divarasib (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug)…
  7. Study sites: 40 to 48v34
  8. Study sites: 39 to 40v33
  9. Study sites: 37 to 39v32
  10. Study sites: 33 to 37v31
  11. Study sites: 30 to 33v30
  12. Study sites: 28 to 30v29
  13. Study sites: 27 to 28v28
  14. Re-verified, no change to tracked fieldsv27
  15. Primary endpoints: 1 to 2 Interventions: Atezolizumab (Drug), Ipatasertib (Drug), Tiragolumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug), Tiragolumab and… · Secondary endpoints shortened, about 25 words · Eligibility criteria expanded, about 1 wordv26 Show 3 more changesShow less
    • Interventions: Atezolizumab (Drug), Ipatasertib (Drug), Tiragolumab (Drug) to Atezolizumab (Drug), Bevacizumab (Drug), Entrectinib (Drug), Inavolisib (Drug), Ipatasertib (Drug), Tiragolumab (Drug), Tiragolumab and…
    • Secondary endpoints shortened, about 25 words
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  16. Study sites: 24 to 27v25
  17. Re-verified, no change to tracked fieldsv24
  18. Site details revised at 1 of 24 sitesv23
  19. Study sites: 22 to 24v22
  20. 5 versions Re-verified since Aug 9, 2024, no change to tracked fieldsv17-v21
  21. Site details revised at 1 of 22 sitesv16
  22. Re-verified, no change to tracked fieldsv15
  23. Study sites: 20 to 22 Interventions: Ipatasertib (Drug) to Atezolizumab (Drug), Ipatasertib (Drug), Tiragolumab (Drug) · Secondary endpoints: 2 to 1 · Study arms: 1 to 2v14 Show 3 more changesShow less
    • Interventions: Ipatasertib (Drug) to Atezolizumab (Drug), Ipatasertib (Drug), Tiragolumab (Drug)
    • Secondary endpoints: 2 to 1
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  24. Re-verified, no change to tracked fieldsv13
  25. Site details revised at 2 of 20 sitesv12
  26. Study sites: 17 to 20v11
  27. Study sites: 15 to 17v10
  28. Study sites: 10 to 15 Primary and study completion dates: May 1, 2033 to Mar 1, 2033v9 Show 1 more changeShow less
    • Primary and study completion dates: May 1, 2033 to Mar 1, 2033
  29. Study sites: 6 to 10v8
  30. Study sites: 5 to 6v7
  31. Phase: Phase 4 to Phase 3 Study sites: 4 to 5v6 Show 1 more changeShow less
    • Study sites: 4 to 5
  32. Study sites: 3 to 4v5
  33. Study sites: 2 to 3v4
  34. Study sites: 1 to 2v3
  35. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Trial Details
NCT Number NCT05862285
Lead Sponsor Hoffmann-La Roche
Conditions Cancer
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov